Cover Image
市場調查報告書

B型肝炎:全球臨床實驗檢討

Hepatitis B Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 217846
出版日期 內容資訊 英文 785 Pages
訂單完成後即時交付
價格
Back to Top
B型肝炎:全球臨床實驗檢討 Hepatitis B Global Clinical Trials Review, H2, 2016
出版日期: 2016年08月24日 內容資訊: 英文 785 Pages
簡介

B型肝炎是肝臟感染B型肝炎病毒(HBV)而發炎的疾病。這是全球性重大健康問題之一,是病毒性肝炎中最嚴重的種類。兒童感染慢性肝炎的風險極高,除了B型肝炎病毒(HBV)之外也會由酒精般毒素產生。此外也會經由感染者的血液、精液、陰道液、其他體液擴大傳染。

本報告提供B型肝炎相關臨床研究最新趨勢分析,提供您疾病·治療方法概要,及G7各國的臨床實驗狀況,各地區、Phase、階段的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

簡介

  • B型肝炎
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 前五名國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量: B型肝炎臨床實驗數量上感染疾病臨床實驗數量所佔的比例

Phase別臨床實驗數量: G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量: B型肝炎臨床實驗數量上感染疾病臨床實驗數量所佔的比例

Phase別臨床實驗數量: E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

未完成的臨床實驗 B型肝炎

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - B型肝炎治療藥

有潛力的藥劑

  • 最新臨床實驗新聞: B型肝炎

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Sanofi
    • Bukwang Pharm.Co., Ltd.
    • Dynavax Technologies Corporation
    • LG Life Sciences, Ltd.
  • 有代表性的研究機關/醫院臨床實驗概要
    • National Taiwan University Hospital
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • The National Institute of Allergy and Infectious Diseases
    • Sun Yat-sen University
    • Third Affiliated Hospital of Sun Yat-sen University
    • Yonsei University
    • The Foundation for Liver Research
    • Chinese University of Hong Kong
    • The University of Hong Kong
    • French National Agency for Research on AIDS and Viral Hepatitis

5大臨床實驗簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3663CTIDB

GlobalData's clinical trial report, "Hepatitis B Global Clinical Trials Review, H2, 2016" provides an overview of Hepatitis B clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Hepatitis B
      • Aug 02, 2016: ContraVir Reports Positive Data from Phase 1b Study of CMX157
      • Jul 21, 2016: Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial's Safety Review Committee
      • Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B
      • Jun 21, 2016: ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B
      • Jun 07, 2016: Replicor announces publication of its REP 101 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection
      • Jun 07, 2016: Replicor announces publication of its REP 102 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection
      • Jun 01, 2016: ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B
      • Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
      • May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Hepatitis B Therapeutics, Global, Clinical Trials by Region, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Hepatitis B Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top